<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084810</url>
  </required_header>
  <id_info>
    <org_study_id>NN7777-4087</org_study_id>
    <secondary_id>2013-003163-63</secondary_id>
    <secondary_id>U1111-1145-6620</secondary_id>
    <nct_id>NCT02084810</nct_id>
  </id_info>
  <brief_title>Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects</brief_title>
  <official_title>A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the bioequivalence
      of eptacog alfa A 6 mg and NovoSeven® in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>After a single i.v. injection based on FVIIa activity assessments up to 36 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration</measure>
    <time_frame>After a single i.v. injection based on FVIIa activity assessments up to 36 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (including serious adverse events)</measure>
    <time_frame>Assessed up to 7 weeks following first trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibodies</measure>
    <time_frame>Assessed up to 7 weeks following first trial product administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NovoSeven®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eptacog alfa A 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activated recombinant human factor VII</intervention_name>
    <description>All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.
Each subject will be allocated to two treatment periods separated by a wash-out period of a week.</description>
    <arm_group_label>NovoSeven®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eptacog alfa (activated)</intervention_name>
    <description>All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.</description>
    <arm_group_label>Eptacog alfa A 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, age 18-55 years, both inclusive, at the time of signing informed consent

          -  Body Mass Index (BMI) 18.5-30 kg/m^2, both inclusive

          -  Good general health based on assessment of medical history, vital signs, physical
             examination, ECG (electrocardiogram), and laboratory data at screening, as judged by
             the investigator

        Exclusion Criteria:

          -  Known history of thromboembolic event(s) or potential thromboembolic risk as judged by
             the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

